Purpose : The purpose of the present study was to assess the risk of second cancers in patients with hairy cell leukemia (HCL). Patients and Methods: We investigated the incidence of additional cancers in those patients registered in the nationwide registry of the Italian Cooperative Group for the Study of HCL, asking the cooperating centers for additional information on initial and subsequent therapies and on time and type of second malignancies, if they developed. Here we report the final results of this survey, consisting of 54 cases of second malignancies (excluding nine cases of epithelial skin cancer) which developed in 54 patients of 1,022 with adequate follow-up. Results: The cumulative risk of development of a second cancer was 5%, 10%, and 14% at 5, 10, and 15 years, respectively. The incidence of second malignancies was not significantly higher than the expected rate (standardized incidence ratio [SIR], 1.01; 95% confidence interval [CI], 0.74 to 1.33; P = 1.0). However, the SIR of non-Hodgkin´s lymphoma in the entire cohort was 5.3 (95% Cl, 1.9 to 11.5). Second malignancies occurred in eight (4.7%) of 386 patients who never received interferon (IFN), nine (5.9%) of 495 patients treated with IFN at the time of diagnosis, and seven (6.9%) of 102 patients who received IFN as second-line therapy. These differences were not statistically significant. Analysis of the separate calendar periods did not reveal any particular trends with respect to variations in SIR. Conclusion: The present study does not support the suspicion that patients with HCL are at increased risk of additional second malignancies, although the incidence of lymphoid neoplasms was significantly higher than expected. In addition, our data indicate that IFN therapy did not exert an oncogenic effect in such patients.

Risk of second cancer in patients with hairy cell leukemia: Long-term follow-up / Federico, Massimo; Pl, Zinzani; A., Frassoldati; Vinceti, Marco; A., Mode; L., Annino; T., Chisesi; G., Pagnucco; R., Invernizzi; M., Spriano; L., Resegotti; M., Bendandi; Ee, Damasio. - In: JOURNAL OF CLINICAL ONCOLOGY. - ISSN 0732-183X. - STAMPA. - 20:3(2002), pp. 638-646. [10.1200/jco.2002.20.3.638]

Risk of second cancer in patients with hairy cell leukemia: Long-term follow-up

FEDERICO, Massimo;VINCETI, Marco;
2002

Abstract

Purpose : The purpose of the present study was to assess the risk of second cancers in patients with hairy cell leukemia (HCL). Patients and Methods: We investigated the incidence of additional cancers in those patients registered in the nationwide registry of the Italian Cooperative Group for the Study of HCL, asking the cooperating centers for additional information on initial and subsequent therapies and on time and type of second malignancies, if they developed. Here we report the final results of this survey, consisting of 54 cases of second malignancies (excluding nine cases of epithelial skin cancer) which developed in 54 patients of 1,022 with adequate follow-up. Results: The cumulative risk of development of a second cancer was 5%, 10%, and 14% at 5, 10, and 15 years, respectively. The incidence of second malignancies was not significantly higher than the expected rate (standardized incidence ratio [SIR], 1.01; 95% confidence interval [CI], 0.74 to 1.33; P = 1.0). However, the SIR of non-Hodgkin´s lymphoma in the entire cohort was 5.3 (95% Cl, 1.9 to 11.5). Second malignancies occurred in eight (4.7%) of 386 patients who never received interferon (IFN), nine (5.9%) of 495 patients treated with IFN at the time of diagnosis, and seven (6.9%) of 102 patients who received IFN as second-line therapy. These differences were not statistically significant. Analysis of the separate calendar periods did not reveal any particular trends with respect to variations in SIR. Conclusion: The present study does not support the suspicion that patients with HCL are at increased risk of additional second malignancies, although the incidence of lymphoid neoplasms was significantly higher than expected. In addition, our data indicate that IFN therapy did not exert an oncogenic effect in such patients.
2002
20
3
638
646
Risk of second cancer in patients with hairy cell leukemia: Long-term follow-up / Federico, Massimo; Pl, Zinzani; A., Frassoldati; Vinceti, Marco; A., Mode; L., Annino; T., Chisesi; G., Pagnucco; R., Invernizzi; M., Spriano; L., Resegotti; M., Bendandi; Ee, Damasio. - In: JOURNAL OF CLINICAL ONCOLOGY. - ISSN 0732-183X. - STAMPA. - 20:3(2002), pp. 638-646. [10.1200/jco.2002.20.3.638]
Federico, Massimo; Pl, Zinzani; A., Frassoldati; Vinceti, Marco; A., Mode; L., Annino; T., Chisesi; G., Pagnucco; R., Invernizzi; M., Spriano; L., Resegotti; M., Bendandi; Ee, Damasio
File in questo prodotto:
File Dimensione Formato  
Risk of second cancer in.......pdf

Accesso riservato

Tipologia: Versione pubblicata dall'editore
Dimensione 249.69 kB
Formato Adobe PDF
249.69 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/310243
Citazioni
  • ???jsp.display-item.citation.pmc??? 4
  • Scopus 52
  • ???jsp.display-item.citation.isi??? 40
social impact